Skip to main content

ESTUDIO DE LAS PROTEINAS INTEGRANTES DE LOS CANALOSOMAS KV1.5 Y KV4.3 COMO DIANAS PARA LA FIBRILACION AURICULAR

PID2019-104366RB-C21

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 20
Encontrada(s) 1 página(s)

Investigo. Repositorio Institucional de la Universidade de Vigo
Publication Artículo científico (JournalArticle)

Novel loss-of-function KCNA5 variants in pulmonary arterial hypertension

  • Vera-Zambrano, Alba
  • Lago Docampo, Mauro
  • Gallego, Natalia
  • Franco-Gonzalez, Juan Felipe
  • Morales-Cano, Daniel
  • Cruz Utrilla, Alejandro
  • Villegas-Esguevillas, Marta
  • Fernández-Malavé, Edgar
  • Escribano Subías, Pilar
  • Tenorio Castaño, Jair Antonio
  • Perez-Vizcaino, Francisco
  • Valverde Pérez, Diana
  • Mourin Gonzalez, Maria Teresa
  • Cogolludo Agustin, Miguel Angel
Reduced expression and/or activity of Kv1.5 channels (encoded by KCNA5) is a common hallmark in human or experimental pulmonary arterial hypertension (PAH). Likewise, genetic variants in KCNA5 have been found in patients with PAH, but their functional consequences and potential impact on the disease are largely unknown. Herein, this study aimed to characterize the functional consequences of seven KCNA5 variants found in a cohort of patients with PAH. Potassium currents were recorded by patch-clamp technique in HEK293 cells transfected with wild-type or mutant Kv1.5 cDNA. Flow cytometry, Western blot, and confocal microscopy techniques were used for measuring protein expression and cell apoptosis in HEK293 and human pulmonary artery smooth muscle cells. KCNA5 variants (namely, Arg184Pro and Gly384Arg) found in patients with PAH resulted in a clear loss of potassium channel function as assessed by electrophysiological and molecular modeling analyses. The Arg184Pro variant also resulted in a pronounced reduction of Kv1.5 expression. Transfection with Arg184Pro or Gly384Arg variants decreased apoptosis of human pulmonary artery smooth muscle cells compared with the wild-type cells, demonstrating that KCNA5 dysfunction in both variants affects cell viability. Thus, in addition to affecting channel activity, both variants were associated with impaired apoptosis, a crucial process linked to the disease. The estimated prevalence of dysfunctional KCNA5 variants in the PAH population analyzed was around 1%. The data indicate that some KCNA5 variants found in patients with PAH have critical consequences for channel function, supporting the idea that KCNA5 pathogenic variants may be a causative or contributing factor for PAH., Comunidad de Madrid | Ref. B2017/BMD-3727, Instituto de Salud Carlos III | Ref. PI18/01233, Instituto de Salud Carlos III | Ref. PI21/01593, Agencia Estatal de Investigación | Ref. PID2020-117939RB-I00, Agencia Estatal de Investigación | Ref. PID2019-104366RB-C21, Agencia Estatal de Investigación | Ref. PID2019-107363RB-I00, Xunta de Galicia | Ref. ED481A-2018/304
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Kv1.3 channels are novel determinants of macrophage-dependent endothelial dysfunction in angiotensin II-induced hypertension in mice

  • Olivencia, Miguel A.
  • Martínez-Casales, Marta
  • Peraza, Diego A.
  • García-Redondo, Ana B.
  • Mondéjar‐Parreño, Gema
  • Hernanz, Raquel
  • Salaices, Mercedes
  • Cogolludo, Angel
  • Pennington, Michael W.
  • Valenzuela, Carmen
  • Briones, Ana M.
[Background and Purpose]: KV1.3 channels are expressed in vascular smooth muscle cells (VSMCs), where they contribute to proliferation rather than contraction and participate in vascular remodelling. KV1.3 channels are also expressed in macrophages, where they assemble with KV1.5 channels (KV1.3/KV1.5), whose activation generates a KV current. In macrophages, the KV1.3/KV1.5 ratio is increased by classical activation (M1). Whether these channels are involved in angiotensin II (AngII)-induced vascular remodelling, and whether they can modulate the macrophage phenotype in hypertension, remains unknown. We characterized the role of KV1.3 channels in vascular damage in hypertension., [Experimental Approach]: We used AngII-infused mice treated with two selective KV1.3 channel inhibitors (HsTX[R14A] and [EWSS]ShK). Vascular function and structure were measured using wire and pressure myography, respectively. VSMC and macrophage electrophysiology were studied using the patch-clamp technique; gene expression was analysed using RT-PCR., [Key Results]: AngII increased KV1.3 channel expression in mice aorta and peritoneal macrophages which was abolished by HsTX[R14A] treatment. KV1.3 inhibition did not prevent hypertension, vascular remodelling, or stiffness but corrected AngII-induced macrophage infiltration and endothelial dysfunction in the small mesenteric arteries and/or aorta, via a mechanism independent of electrophysiological changes in VSMCs. AngII modified the electrophysiological properties of peritoneal macrophages, indicating an M1-like activated state, with enhanced expression of proinflammatory cytokines that induced endothelial dysfunction. These effects were prevented by KV1.3 blockade., [Conclusions and Implications]: We unravelled a new role for KV1.3 channels in the macrophage-dependent endothelial dysfunction induced by AngII in mice which might be due to modulation of macrophage phenotype., This work was funded by the Ministerio de Economía y Competitividad; AEI-FEDER, EU grants: SAF2016-75021-R and PID2019-104366RB-C21 (to C.V.), SAF2016-80305-P (to A.M.B. and M.S.), and SAF2016-77222-R (to A.C.); Instituto de Salud Carlos III CIBERCV program: CB16/11/00286 (to M.S.) and CB/11/00222 (to C.V.); Consejo Superior de Investigaciones Científicas grants: PIE 201820E104 and 2019AEP148 (to C.V.) and Comunidad de Madrid grant: B2017/BMD-3676-AORTASANA (to M.S.) and B2017/BMD-3727 (to A.C.) with funds co-financed by ERDF (FEDER) Funds from the European Commission, “A way of making Europe”; and Comunidad de Madrid-Universidad Autónoma de Madrid grant: SI1-PJ1-2019-00321 (to A.B.G.-R.).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Kv1.5-Kvb1.3 Recycling is PKC-Dependent

  • Macías, Álvaro
  • Cruz, Alicia de la
  • Peraza, Diego A.
  • Benito-Bueno, Ángela de
  • González, Teresa
  • Valenzuela, Carmen
© 2021 by the authors., KV1.5 channel function is modified by different regulatory subunits. KVβ1.3 subunits assemble with KV1.5 channels and induce a fast and incomplete inactivation. Inhibition of PKC abolishes the KVβ1.3-induced fast inactivation, decreases the amplitude of the current KV1.5–KVβ1.3 and modifies their pharmacology likely due to changes in the traffic of KV1.5–KVβ1.3 channels in a PKC-dependent manner. In order to analyze this hypothesis, HEK293 cells were transfected with KV1.5–KVβ1.3 channels, and currents were recorded by whole-cell configuration of the patch-clamp technique. The presence of KV1.5 in the membrane was analyzed by biotinylation techniques, live cell imaging and confocal microscopy approaches. PKC inhibition resulted in a decrease of 33 ± 7% of channels in the cell surface due to reduced recycling to the plasma membrane, as was confirmed by confocal microscopy. Live cell imaging indicated that PKC inhibition almost abolished the recycling of the KV1.5–KVβ1.3 channels, generating an accumulation of channels into the cytoplasm. All these results suggest that the trafficking regulation of KV1.5–KVβ1.3 channels is dependent on phosphorylation by PKC and, therefore, they could represent a clinically relevant issue, mainly in those diseases that exhibit modifications in PKC activity., This research was funded by Ministerio de Ciencia e Innovación (MICINN) Spain SAF2016-75021-R and PID2019-104366RB-C21 (to C.V. and T.G.), the Instituto de Salud Carlos III CIBERCV program CB/11/00222 (to C.V.), and the Consejo Superior de Investigaciones Científicas grants: PIE201820E104 and 2019AEP148 (to C.V.). The cost of this publication was paid in part by funds from the European Fund for Economic and Regional Development (FEDER). A.M. holds a postdoctoral contract at CNIC. A.d.l.C. and D.A.P. held CSIC contracts. A.d.B.-B. holds an MICINN predoctoral contract (BES-2017-080184).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Graphene Particles Interfere with Pro-Inflammatory Polarization of Human Macrophages: Functional and Electrophysiological Evidence

  • Povo-Retana, Adrián
  • Mojena, Marina
  • Boscá, Alberto
  • Pedrós, Jorge
  • Peraza, Diego A.
  • Valenzuela, Carmen
  • Laparra, José Moisés
  • Calle, Fernando
  • Boscá, Lisardo
© 2021 The Authors, The interaction of two types of fragmented graphene particles (30–160 nm) with human macrophages is studied. Since macrophages have significant phagocytic activity, the incorporation of graphene particles into cells has an effect on the response to functional polarization stimuli, favoring an anti-inflammatory profile. Incubation of macrophages with graphene foam particles, prepared by chemical vapor deposition, and commercially available graphene nanoplatelet particles does not affect cell viability when added at concentrations up to 100 µg mL−1; macrophages exhibit differential quantitative responses to each type of graphene particles. Although both materials elicit similar increases in the release of reactive oxygen species, the impact on the transcriptional regulation associated with the polarization profile is different; graphene nanoplatelets significantly modify this transcriptomic profile. Moreover, these graphene particles differentially affect the motility and phagocytosis of macrophages. After the incorporation of both graphene types into the macrophages, they exhibit specific responses in terms of the mitochondrial oxygen consumption and electrophysiological potassium currents at the cell plasma membrane. These data support the view that the physical structure of the graphene particles has an impact on human macrophage responses, paving the way for the development of new mechanisms to modulate the activity of the immune system., This work was supported by grants SAF2017-82436R, PID2019-104366RB-C21, RyC-2015-18968, and PID2020-113238RB-I00 from MINECO/AEI/FEDER/EU; S2017/BMD-3686 and NMAT2D-CM P2018/ NMT-4511 from Comunidad de Madrid; CIVP18A3864 from Fundación Ramón Areces; Ayuda para la incorporación y retención de talento doctor, Programa Propio de I+D+i 2019 and 2020 from UPM and CIBERCV and CIBERHED (funded by the Instituto de Salud Carlos III) and Fondos FEDER.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Identification of a critical binding site for local anaesthetics in the side pockets of Kv1 channels

  • Kiper, Aytug K.
  • Bedoya, Mauricio
  • Stalke, Sarah
  • Marzian, Stefanie
  • Ramírez, David
  • Cruz, Alicia de la
  • Peraza, Diego A.
  • Vera-Zambrano, Alba
  • Márquez Montesinos, José C. E.
  • Arévalo Ramos, Bárbara A.
  • Rinné, Susanne
  • González, Teresa
  • Valenzuela, Carmen
  • González, Wendy
  • Decher, Niels
© 2021 The Authors., [Background and Purpose]: Local anaesthetics block sodium and a variety of potassium channels. Although previous studies identified a residue in the pore signature sequence together with three residues in the S6 segment as a putative binding site, the precise molecular basis of inhibition of Kv channels by local anaesthetics remained unknown. Crystal structures of Kv channels predict that some of these residues point away from the central cavity and face into a drug binding site called side pockets. Thus, the question arises whether the binding site of local anaesthetics is exclusively located in the central cavity or also involves the side pockets. [Experimental Approach]: A systematic functional alanine mutagenesis approach, scanning 58 mutants, together with in silico docking experiments and molecular dynamics simulations was utilized to elucidate the binding site of bupivacaine and ropivacaine. [Key Results]: Inhibition of Kv1.5 channels by local anaesthetics requires binding to the central cavity and the side pockets, and the latter requires interactions with residues of the S5 and the back of the S6 segments. Mutations in the side pockets remove stereoselectivity of inhibition of Kv1.5 channels by bupivacaine. Although binding to the side pockets is conserved for different local anaesthetics, the binding mode in the central cavity and the side pockets shows considerable variations. [Conclusion and Implications]: Local anaesthetics bind to the central cavity and the side pockets, which provide a crucial key to the molecular understanding of their Kv channel affinity and stereoselectivity, as well as their spectrum of side effects., The study was supported by the Ministerio de Ciencia e Innovación (MICINN, Spain) Grants SAF2016-75021-R and PID2019-104366RB-C21 (to C.V. and T.G.); the European Regional Development Fund (Fondo Europeo de Desarrollo Regional [FEDER]) and the Instituto de Salud Carlos III CIBERCV programme CB/11/00222 (to C.V. and T.G.); the Consejo Superior de Investigaciones Científicas (CSIC) Grants PIE201820E104 and 2019AEP148 (to C.V.); the Fondo Nacional de Desarrollo Científico y Tecnológico (FONDECYT) 1191133 and the Fondo de Equipamiento Científico y Tecnológico (FONDEQUIP) 160063 grants from ANID (to W.G.); and the Deutsche Forschungsgemeinschaft (DFG) Grant DE1482-4/1 to N.D.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

IQM-PC332, a Novel DREAM Ligand with Antinociceptive Effect on Peripheral Nerve Injury-Induced Pain

  • Socuéllamos, Paula G.
  • Olivos-Oré, Luis A.
  • Barahona, María Victoria
  • Cercós, Pilar
  • Pérez Pascual, Marta
  • Arribas-Blázquez, Marina
  • Naranjo, José Ramón
  • Valenzuela, Carmen
  • Gutiérrez-Rodríguez, Marta
  • Artalejo, Antonio R.
Neuropathic pain is a form of chronic pain arising from damage of the neural cells that sense, transmit or process sensory information. Given its growing prevalence and common refractoriness to conventional analgesics, the development of new drugs with pain relief effects constitutes a prominent clinical need. In this respect, drugs that reduce activity of sensory neurons by modulating ion channels hold the promise to become effective analgesics. Here, we evaluated the mechanical antinociceptive effect of IQM-PC332, a novel ligand of the multifunctional protein downstream regulatory element antagonist modulator (DREAM) in rats subjected to chronic constriction injury of the sciatic nerve as a model of neuropathic pain. IQM-PC332 administered by intraplantar ( 0.01–10 μg) or intraperitoneal (0.02–1 μg/kg) injection reduced mechanical sensitivity by ≈100% of the maximum possible effect, with ED50 of 0.27 ± 0.05 μg and 0.09 ± 0.01 μg/kg, respectively. Perforated-patch whole-cell recordings in isolated dorsal root ganglion (DRG) neurons showed that IQM-PC332 (1 and 10 μM) reduced ionic currents through voltage-gated K+ channels responsible for A-type potassium currents, low, T-type, and high voltage-activated Ca2+ channels, and transient receptor potential vanilloid-1 (TRPV1) channels. Furthermore, IQM-PC332 (1 μM) reduced electrically evoked action potentials in DRG neurons from neuropathic animals. It is suggested that by modulating multiple DREAM–ion channel signaling complexes, IQM-PC332 may serve a lead compound of novel multimodal analgesics., This research was funded by Universidad Complutense de Madrid grants: PR75/18- 21593 and FEI20/35 (to A.R.A.), and Ministerio de Ciencia e Innovación, AEI-FEDER, EU grants: SAF2016-75021-R and PID2019-104366RB-C21 (to C.V.), PID2019-109155RB-I00 (to A.R.A.), PID2019- 104366RB-C22 (to M.G.-R), Instituto de Salud Carlos III CIBERCV program: CB/11/00222 (to C.V.); Consejo Superior de Investigaciones Científicas grants: PIE202180E073 (to M.G.-R.), PIE201820E104 and 2019AEP148 (to C.V.). P.G.S. was funded with a fellowship from the Ministerio de Ciencia e Innovación (FPU17/02731)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A novel loss of function mutation of the voltage gated potassium channel Kv10.2 involved in epilepsy and autism

  • Galán-Vidal, Jesús
  • Socuéllamos, Paula G.
  • Baena-Nuevo, M.
  • Contreras, Lizbeth
  • González, Teresa
  • Pérez-Poyato, María S.
  • Valenzuela, Carmen
  • González-Lamuño, Domingo
  • Gandarillas, Alberto
[Background]: Novel developmental mutations associated with disease are a continuous challenge in medicine. Clinical consequences caused by these mutations include neuron and cognitive alterations that can lead to epilepsy or autism spectrum disorders. Often, it is difficult to identify the physiological defects and the appropriate treatments. [Results]: We have isolated and cultured primary cells from the skin of a patient with combined epilepsy and autism syndrome. A mutation in the potassium channel protein Kv10.2 was identified. We have characterised the alteration of the mutant channel and found that it causes loss of function (LOF). Primary cells from the skin displayed a very striking growth defect and increased differentiation. In vitro treatment with various carbonic anhydrase inhibitors with various degrees of specificity for potassium channels, (Brinzolamide, Acetazolamide, Retigabine) restored the activation capacity of the mutated channel. Interestingly, the drugs also recovered in vitro the expansion capacity of the mutated skin cells. Furthermore, treatment with Acetazolamide clearly improved the patient regarding epilepsy and cognitive skills. When the treatment was temporarily halted the syndrome worsened again. [Conclusions]: By in vitro studying primary cells from the patient and the activation capacity of the mutated protein, we could first, find a readout for the cellular defects and second, test pharmaceutical treatments that proved to be beneficial. The results show the involvement of a novel LOF mutation of a Potassium channel in autism syndrome with epilepsy and the great potential of in vitro cultures of primary cells in personalised medicine of rare diseases., The study was funded by ISCIII-FIS/FEDER grants PI14/00900, PI17/01307 and PI20/00880 (AG), CIBERCV program CB/11/00222, CSIC 2019AEP148 (CV) and MINECO/AEI-FEDER PID2019-104366RB-C21 (CV and TG). The funding bodies did not have a role in the study, collection, analysis, interpretation of data or in writing the manuscript.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Development of pharmacological tools to study the kv4.3 channelosome in atrial fibrillation

  • Viedma, Carmen
  • Sandin, P.
  • Bonache de Marcos, María Ángeles
  • Martín-Martínez, Mercedes
  • Valenzuela, Carmen
  • Gutiérrez-Rodríguez, Marta
Resumen del trabajo presentado en el XX National Meeting of the Spanish Society of Medicinal Chemistry, celebrado en Santiago de Compostela (España) del 19 al 22 de junio de 2022., Ion channels are macromolecular complexes present in the plasma membrane and in intracellular organelles of the cells, where they play important functions, such as smooth muscle contraction or secretion of hormones. The dysfunction of these channels results in several disorders named channelopathies, which represent a challenge for study and treatment.[1] We are focused on voltage-gated potassium channels, specifically on KV4.3 and its role in atrial fibrillation (AF). KV4.3 channel is expressed in smooth muscle, heart and brain. Its activation generates outward currents operating at subthreshold membrane potentials as recorded from myocardial cells (ITO, transient outward current). KV4.3 plays a key role in AF, the most common cardiac arrhythmia, with an estimated prevalence in the general population of 1.5–2%. However, current antiarrhythmic drugs for AF prevention have limited efficacy and considerable potential for adverse effects.[2] To reproduce the ITO currents, KV4.3 channels need to assemble with other subunits, forming channelosome. KChIPs (Potassium Channel Interacting Proteins), which belong to the calcium binding protein superfamily, forms the KV4.3 channelosome, along with other proteins.[3] To study the complex interaction of KV4.3 channelosome and the development of modulators, the interplay of different techniques is central to advance knowledge. In this regard, the development of novel KChIPs modulators and fluorescent biosensors constitutes invaluable pharmacological tools to unravel the KV4 channelosome and its role in AF.[3] In this communication, we will describe preliminary results towards the identification of new pharmacological tools to study the KChIPs/KV4 interaction., This work was supported by the projects: PID2019-104366RB-C21, PID2019-104366RB-C22, PID2020-114256RB-I00 and PID2020-119805RB-I00 funded by MCIN/ AEI /10.13039/501100011033; and the projects PIE202180E073 and 2019AEP148 funded by CSIC. C. Viedma Barba holds the grant PRE2020-093542 and M. Valencia holds the grant PRE2020-093950, both funded by MCIN/AEI/10.13039/501100011033. A. Pérez-Lara holds the grant RYC2018-023837-I funded by MCIN/AEI/10.13039/501100011033 and by “ESF Investing in your future”.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Effects of IQM-110 on Kv1.5/Kvß2.1 channels

  • Valencia, María
  • Benito-Bueno, Ángela de
  • Socuéllamos, Paula G.
  • Bonache de Marcos, María Ángeles
  • Viedma, Carmen
  • Martín-Martínez, Mercedes
  • Gutiérrez-Rodríguez, Marta
  • Valenzuela, Carmen
Resumen del trabajo presentado en el VIII Congreso Red Española de Canales Sónicos, celebrado en Alicante (España) del 24 al 27 de mayo de 2022., The outward potassium current IKur is the main responsible of the atrial repolarization process and it is generated by the activation of KV1.5 channels, widely expressed in human atria. It is known that mutations in KCNA5 gene, which induce both gain- and loss-of-function in KV1.5 channel, enhance atrial fibrillation susceptibility. Thus, these channels represent a pharmacological target for the development of antiarrhythmic drugs useful in the treatment of supraventricular arrhythmias. KV1.5 channels assembly with several regulatory subunits such as KVß. It has been described that KVß2.1 interacts with KV1.5. Our research group has demonstrated that the molecule IQM-110 produces electrophysiological effects on the KV1.5. The aim of the present study is to analyze the electrophysiological effects of IQM-110 on KV1.5 channels when it was expressed together with the regulatory subunit KVß2.1. In order to achieve this objective, Ltk- cell line constitutively expressing KVß2.1 and with an induced expression of KV1.5 were used. Currents were recorded using the whole-cell configuration of the patch-clamp technique. The effects of IQM-110 on KV1.5/Kvß2.1 current were concentration-dependent with an IC50 of 166¿M (n=64). This compound at 100¿M produced a time-dependent block, inducing a: 1) faster activation (¿=2.8±0.3 vs. 4.1±0.3 ms, n=10, p<0.01), 2) faster inactivation reducing the slow time constant, (¿slow=3172.6±113.8 vs. 629.1±43.8ms, n=5, p<0.001), and 3) slower deactivation kinetics, (¿slow=73.5±3.5 vs. 115.2±12.1ms and ¿fast=19.5±1.3 vs. 27.9±1.9ms, n=10, p<0.01 and p<0.5 respectively). These results are consistent with an open channel block mechanism. Finally, IQM-110 (100 ¿M) enhanced the degree of use-dependent block of the current (1.7±0.4 vs. 47.7±2.4%, n=5, p<0.001). This phenomenon was explained by a slowing of the recovery process in the presence of IQM-110 (¿r=462.6±94.9 vs. 3545.0±254.1ms, n=5, p<0.001). In summary, IQM-110 modulates KV1.5/KVß2.1 channels consistent with an open channel block mechanism., Funded by: Grants SAF2016-75021-R, RTI2018-097189-B-C22 funded by MCIN/AEI/10.13039/501100011033 and by ¿ERDF A way of making Europe¿; Grants PID2019-104366RB-C21, PID2019-104366RB-C22, PID2020-113238RB-I00 funded by MCIN/AEI/ 10.13039/501100011033; Grant CB/11/00222 funded by ISCIII CIBERCV; Grants PIE202180E073 and 2019AEP148 funded by CSIC. Grants BES-2017-080184, PRE-2020-093950, BES-2010-036573 and FPU17/02731 funded by MCIN/AEI/ 10.13039/501100011033 and by ¿ESF Investing in your future.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Electrophysiological effects of IQM-266 on Itof. Role of cardiac beta subunits

  • Benito-Bueno, Ángela de
  • Socuéllamos, Paula G.
  • Cercós, Pilar
  • Izquierdo García, Carolina
  • Martín-Martínez, Mercedes
  • Delgado, Carmen
  • Gutiérrez-Rodríguez, Marta
  • Valenzuela, Carmen
Trabajo presentado en el VIII Congreso Red Española de Canales Sónicos, celebrado en Alicante (España) del 24 al 27 de mayo de 2022., The transient outward potassium current (Itof), responsible for the repolarization of cardiac action potential, is generated by the activation of KV4 channels assembled with KChIP2 and other accessory subunits, such as DPP6 and KCNE2. To test the hypothesis that these subunits modify 18 VIII Congreso Red Española de Canales Iónicos the pharmacological response of the channel, we have analyzed the electrophysiological efects of IQM-266 on the currents generated by KV4.3/KChIP2, KV4.3/KChIP2/DPP6, KV4.3/KChIP2/KCNE2 channels and on the total I K and I tof in cardiac myocytes. CHO cells were transiently transfected (KV4.3/KChIP2, KV4.3/KChIP2/DPP6 or KV4.3/KChIP2/KCNE2), and the potassium currents were recorded using the whole-cell patch-clamp technique. In mice cardiac myocytes, potassium currents were recorded by using the perforated patch-clamp technique. Our results indicate that IQM-266 exerts an activating efect on the I K and I tof peak amplitude in cardiac myocytes. To decipher whichbeta subunits were involved in these efects, IQM-266 was studied in CHO cells transfected with the above-mentioned cDNAs. IQM-266, at 3 μM, induced an increase in the KV4.3/KChIP2 current charge, which augmented in the presence of DPP6, whereas it was abolished when KCNE2 was expressed. However, IQM-266 decreased the peak amplitude in transfected cells. In this study we concluded that: i) IQM-266 is a new activator of the I tof in mice cardiac myocytes, ii) DPP6 and KCNE2 modify the pharmacological response of KV4.3/KChIP2 channels to IQM-266, and iii) the presence of either DPP6 or KCNE2 is not enough to reproduce the activator efect observed when IQM-266 was tested on Ito recorded from mouse ventricular myocytes., Grants SAF2016-75021-R, RTI2018-097189-B-C22 funded by MCIN/AEI/10.13039/501100011033 and by ¿ERDF A way of making Europe¿; Grants PID2019-104366RB-C21, PID2019-104366RB-C22, PID2020-113238RB-I00 funded by MCIN/AEI/ 10.13039/501100011033; Grant CB/11/00222 funded by ISCIII CIBERCV; Grants PIE202180E073 and 2019AEP148 funded by CSIC. Grants BES-2017-080184, BES-2010-036573 and FPU17/02731 funded by MCIN/AEI/10.13039/501100011033 and by ¿ESF Investing in your future¿.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

New approaches for the identification of KChIP2 ligands to study the KV4.3 channelosome in atrial fibrillati

  • Viedma, Carmen
  • Martinez-Salas, P.
  • Benito-Bueno, Ángela de
  • Socuéllamos, Paula G.
  • Marín-Olivero, Irene
  • Daniel-Mozo, Miguel
  • Pérez-Lara, Ángel
  • González-Vera, Juan A.
  • Orte, Angel
  • Albert, Armando
  • Martín-Martínez, Mercedes
  • Valenzuela, Carmen
  • Gutiérrez-Rodríguez, Marta
Resumen del trabajo presentado en el VIII Congreso Red Española de Canales iónico, celebrado en Alicante (España) del 24 al 27 de mayo de 2022., Ion channels are macromolecular complexes present in the plasma membrane and in intracellular organelles of the cells, where they play important functions. The dysfunction of these channels results in several disorders named channelopathies, which represent a challenge for study and treatment.[1] We are focused on voltage-gated potassium channels, specifically on KV4.3. Kv4.3 is expressed in smooth muscle, heart and brain. Within the heart, Kv4.3 channels generate the transient outward potassium current (ITO). However, ITO characteristics are only observed when Kv4.3 assemble with accessory subunits as KChIP2 and DPP6. KV4.3 channelosome play a key role in atrial fibrillation (AF),the most common cardiac arrhythmia, with an estimated prevalence in the general population of 1.5–2%. However, current antiarrhythmic drugs for AF prevention have limited efficacy and considerable potential for adverse effects.[2] KChIP2 (Potassium Channel Interacting Protein 2) belongs to the calcium binding protein superfamily. It is the KChIP member predominantly expressed in heart and a key regulator of cardiac action potential duration. The identification of novel KChIP2 ligands could be useful to understand the role of KV4.3 channelosome in AF and it could help to discover new treatments for AF. [3] In this regard, structure-based virtual screening could be an important tool to accelerate the identification of novel KChIP2 ligands. In this communication, we will describe a multidisciplinary approach that, starting with a structurebased virtual screening, followed by an iterative process of synthesis/biological evaluation/docking studies, has led to the identification of new KChIP2 ligands., PID2019-104366RB-C21, PID2019-104366RB-C22, PID2020-114256RB-I00 and PID2020-119805RB-I00 grants funded by MCIN/AEI/10.13039/501100011033; and PIE202180E073 and 2019AEP148 funded by CSIC. C.V.B. holds PRE2020-093542 FPI grant funded by MCIN/AEI/10.13039/501100011033. PGS was recipient of an FPU grant (FPU17/02731). AB-B holds BES-2017-080184 FPI grant and A.P-L.holds RYC2018-023837-I grant both funded by MCIN/ AEI/ 10.13039/501100011033 and by “ESF Investing in your future”
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

New approaches for the identification of KChIP2 ligands to study the KV4.3 channelosome in atrial fibrillati

  • Viedma, Carmen
  • Martinez-Salas, P.
  • Benito-Bueno, Ángela de
  • Socuéllamos, Paula G.
  • Marín-Olivero, Irene
  • Daniel-Mozo, Miguel
  • Pérez-Lara, Ángel
  • González-Vera, Juan A.
  • Orte, Angel
  • Albert, Armando
  • Martín-Martínez, Mercedes
  • Valenzuela, Carmen
  • Gutiérrez-Rodríguez, Marta
Resumen del trabajo presentado en el VIII Congreso Red Española de Canales iónico, celebrado en Alicante (España) del 24 al 27 de mayo de 2022., Ion channels are macromolecular complexes present in the plasma membrane and in intracellular organelles of the cells, where they play important functions. The dysfunction of these channels results in several disorders named channelopathies, which represent a challenge for study and treatment.[1] We are focused on voltage-gated potassium channels, specifically on KV4.3. Kv4.3 is expressed in smooth muscle, heart and brain. Within the heart, Kv4.3 channels generate the transient outward potassium current (ITO). However, ITO characteristics are only observed when Kv4.3 assemble with accessory subunits as KChIP2 and DPP6. KV4.3 channelosome play a key role in atrial fibrillation (AF),the most common cardiac arrhythmia, with an estimated prevalence in the general population of 1.5–2%. However, current antiarrhythmic drugs for AF prevention have limited efficacy and considerable potential for adverse effects.[2] KChIP2 (Potassium Channel Interacting Protein 2) belongs to the calcium binding protein superfamily. It is the KChIP member predominantly expressed in heart and a key regulator of cardiac action potential duration. The identification of novel KChIP2 ligands could be useful to understand the role of KV4.3 channelosome in AF and it could help to discover new treatments for AF. [3] In this regard, structure-based virtual screening could be an important tool to accelerate the identification of novel KChIP2 ligands. In this communication, we will describe a multidisciplinary approach that, starting with a structurebased virtual screening, followed by an iterative process of synthesis/biological evaluation/docking studies, has led to the identification of new KChIP2 ligands., PID2019-104366RB-C21, PID2019-104366RB-C22, PID2020-114256RB-I00 and PID2020-119805RB-I00 grants funded by MCIN/AEI/10.13039/501100011033; and PIE202180E073 and 2019AEP148 funded by CSIC. C.V.B. holds PRE2020-093542 FPI grant funded by MCIN/AEI/10.13039/501100011033. PGS was recipient of an FPU grant (FPU17/02731). AB-B holds BES-2017-080184 FPI grant and A.P-L.holds RYC2018-023837-I grant both funded by MCIN/ AEI/ 10.13039/501100011033 and by “ESF Investing in your future”
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

IQM-110, a new selective inhibitor of KChIP and its pharmacological effects on Kv4., Kv4./KChIP and Kv4./KChIP currents

  • Benito-Bueno, Ángela de
  • Bonache de Marcos, María Ángeles
  • Viedma, Carmen
  • Martín-Martínez, Mercedes
  • Gutiérrez-Rodríguez, Marta
  • Valenzuela, Carmen
Trabajo presentado en el VIII Congreso Red Española de Canales iónicos, celebrado en Alicante (España) del 24 al 27 de mayo de 2022., Kv4 channels generate outward currents activated at subthreshold membrane potentials and are responsible for the repolarization of both cardiac and neuronal action potentials through ITO (transient outward current) and IA (A-type K+ current), respectively. Kv4 dysfunctions have been identified in cardiac diseases (i.e. Brugada syndrome or atrial fibrillation) as well as in neuronal diseases (i.e. schizophrenia, epilepsy or Alzheimer’s disease). However, Kv4 channels need to assemble with regulatory or β subunits to fully reproduce ITO and IA currents. Among them, we will focus on KChIPs (potassium channel interacting proteins), being KChIP3 predominant in the brain and KChIP2 in both brain and heart. The assembly of these β subunits alters not only the biophysical properties of the channel, but also its pharmacology. For this reason, we have analysed the electrophysiological effects of IQM-22110 (a new compound designed to bind KChIP3) on the currents generated by Kv4.3, Kv4.3/KChIP2 and Kv4.3/KChIP3 channels. CHO cells were transiently transfected (Kv4.3, Kv4.3/KChIP2 or Kv4.3/KChIP3), and the potassium currents were recorded using the whole-cell patch-clamp technique. Our results indicate that IQM-22110 exerts differential effects on Kv4.3, Kv4.3/KChIP2 and Kv4.3/KChIP3 currents. First of all, the concentration-dependence of inhibition was modified, being the IC50 = 5.5 μM for Kv4.3 channels, 10.4 μM for Kv4.3/KChIP2 and exhibited a biphasic curve when KChIP3 is present (IC50(1) = 0.03 μM and IC50(2) = 26.3 μM), suggesting two binding sites for IQM-22110 in this complex. With molecular dynamics and sitedirected mutagenesis, we have identified two aminoacids (Y130 and K166) in KChIP3 critical to the binding of IQM-22110 to its high affinity site. Also, we selected equipotent concentrations of IQM22110 to further study the biophysical effects of this compound on each situation, demonstrating that IQM-22110 binds to the closed-active state of the channel. In this study we concluded that: i) at low concentrations, IQM-22110 is a selective inhibitor of Kv4.3/KChIP3, ii) Y130 and K166 in KChIP3 are critical to the binding of IQM-22110 to the high affinity site in Kv4.3/KChIP3, and iii) IQM-22110 binds to the closed-active state of Kv4.3, Kv4.3/KChIP2 and Kv4.3/KChIP3., Funded by SAF2016-75021-R; PID2019-104366RB-C21, PID2019-104366RB-C22, PID2020-114256RB-I00 and PID2020-119805RB-I00 grants funded by MCIN/AEI/10.13039/501100011033; PIE201820E104, CSIC2019AEP148, PIE202180E073 and 2019AEP148 funded by CSIC; CIBER CB/11/00222. PGS holds an FPU grant (FPU17/02731) funded by Ministerio de Universidades. AB-B holds BES-2017-080184 FPI grant funded by MCIN/AEI/ 10.13039/501100011033 and by “ESF Investing in your future”. C.V.B. holds PRE2020-093542 FPI grant funded by MCIN/AEI/10.13039/501100011033.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Study of kv4.3 channelosome: novel kchip2 ligands as pharmacological tools

  • Martinez-Salas, P.
  • Viedma, Carmen
  • Benito-Bueno, Ángela de
  • Socuéllamos, Paula G.
  • Daniel-Mozo, Miguel
  • Albert, Armando
  • Martín-Martínez, Mercedes
  • Valenzuela, Carmen
  • Gutiérrez-Rodríguez, Marta
Trabajo presentado en el VIII Symposia of medicinal chemistry young researchers, celebrado en Barcelona (España) el 22 de julio de 2022., Ion channels are macromolecular complexes present in the plasma membrane and in intracellular organelles of the cells, where they play important functions. The dysfunction of these channels results in several disorders named channelopathies, which represent a challenge for study and treatment.[1] We are focused on voltage-gated potassium channels, specifically on KV4.3. Within the heart, KV4.3 channels generate the transient outward potassium current (ITO). However, ITO characteristics are only observed when KV4.3 assembles with accessory subunits as KChIP2 and DPP6. KV4.3 channelosome play a key role in atrial fibrillation (AF), the most common cardiac arrhythmia, with an estimated prevalence in the general population of 1.5–2%. However, current antiarrhythmic drugs for AF prevention have limited efficacy and considerable potential for adverse effects.[2] KChIP2 (Potassium Channel Interacting Protein 2) belongs to the calcium binding protein superfamily. It is the KChIP member predominantly expressed in heart and a key regulator of cardiac action potential duration. Novel KChIP2 ligands could be a useful pharmacological tool to understand the role of KV4.3 channelosome in AF and it could help to discover new treatments for AF. [3] In this communication, we will describe a multidisciplinary approach that, starting with a structure-based virtual screening, followed by an iterative process of synthesis/biological evaluation/docking studies, has led to the identification of new KChIP2 ligands., PID2019-104366RB-C21, PID2019-104366RB-C22, PID2020-114256RB-I00 and PID2020-119805RB-I00 grants funded by MCIN/AEI/10.13039/501100011033; and PIE202180E073 and 2019AEP148 funded by CSIC. C.V.B. holds PRE2020-093542 FPI grant funded by MCIN/AEI/10.13039/501100011033. PGS was recipient of an FPU grant (FPU17/02731). AB-B holds BES-2017-080184 FPI grant and A.P-L.holds RYC2018-023837-I grant both funded by MCIN/AEI/ 10.13039/501100011033 and by “ESF Investing in your future”.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Novel loss of function KCNA5 variants in pulmonary arterial hypertension, Running title: Novel loss of function KCNA5 variants in PAH

  • Vera-Zambrano, Alba
  • Lago-Docampo, Mauro
  • Gallego, Natalia
  • Franco-Gonzalez, Juan Felipe
  • Morales-Cano, Daniel
  • Cruz-Utrilla, Alejandro
  • Villegas-Esguevillas, Marta
  • Fernández-Malavé, Edgar
  • Escribano-Subias, Pilar
  • Tenorio, Jair
  • Pérez-Vizcaíno, Francisco
  • Valverde, Diana
  • González, Teresa
  • SICPH investigators
  • Cogolludo, Angel
12 p.-7 fig., Reduced expression and/or activity of Kv1.5 channels (encoded by KCNA5) is a common hallmark in human or experimental pulmonary arterial hypertension (PAH). Likewise, genetic variants in KCNA5 have been found in PAH patients, but their functional consequences and potential impact on the disease are largely unknown. Herein, we aimed to characterize the functional consequences of 7 KCNA5 variants found in a cohort of PAH patients. Potassium currents were recorded by patch-clamp technique in HEK293 cells transfected with WT or mutant Kv1.5 cDNA. Flow cytometry, western blot and confocal microscopy techniques were used for measuring protein expression and cell apoptosis in HEK293 and human pulmonary artery smooth muscle cells (hPASMC). KCNA5 variants found in PAH patients (namely, p.Arg184Pro and p.Gly384Arg) resulted in a clear loss of potassium channel function as assessed by electrophysiological and molecular modelling analyses. The p.Arg184Pro variant also resulted in a pronounced reduction of Kv1.5 expression. Transfection with p.Arg184Pro or p.Gly384Arg variants decreased apoptosis of hPASMCs compared with the WT, demonstrating that KCNA5 dysfunction in both variants affects cell viability. Thus, in addition to affecting channel activity, both variants were associated with impaired apoptosis, a crucial process linked to the disease. The estimated prevalence of dysfunctional KCNA5 variants in the PAH population analyzed was around 1 %. Our data indicate that some KCNA5 variants found PAH patients have critical consequences for channel function supporting the idea that KCNA5 pathogenic variants may be a causative or contributing factor for PAH., This work was supported by Fundación Contra la Hipertensión Pulmonar (FCHP); Ministerio de Ciencia e Innovación [PID2020-117939RB-I00 to AC, PID2019-104366RB-C21 to TG, PID2019-107363RB-I00 to FPV]; Comunidad de Madrid [B2017/BMD-3727 to AC] and Instituto de Salud Carlos III [PI18/01233, PI21/01593] with funds from the European Union (Fondo Europeo de Desarrollo Regional FEDER); and by an annual grant by the FEDER foundation (Federación Española de Enfermedades Raras)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Trabectedin modulates macrophage polarization in the tumor-microenvironment. Role of Kv1.3 and Kv1.5 channels

  • Peraza, Diego A.
  • Povo-Retana, Adrián
  • Mojena, Marina
  • García-Redondo, Ana B.
  • Avilés, Pablo
  • Boscá, Lisardo
  • Valenzuela, Carmen
Immune cells have an important role in the tumor-microenvironment. Macrophages may tune the immune response toward inflammatory or tolerance pathways. Tumor-associated macrophages (TAM) have a string of immunosuppressive functions and they are considered a therapeutic target in cancer. This study aimed to analyze the effects of trabectedin, an antitumor agent, on the tumor-microenvironment through the characterization of the electrophysiological and molecular phenotype of macrophages. Experiments were performed using the whole-cell configuration of the patch-clamp technique in resident peritoneal mouse macrophages. Trabectedin does not directly interact with KV1.5 and KV1.3 channels, but their treatment (16 h) with sub-cytotoxic concentrations of trabectedin increased their KV current due to an upregulation of KV1.3 channels. In vitro generated TAM (TAMiv) exhibited an M2-like phenotype. TAMiv generated a small KV current and express high levels of M2 markers. K+ current from TAMs isolated from tumors generated in mice is a mixture of KV and KCa, and in TAM isolated from tumors generated in trabectedin-treated mice, the current is mostly driven by KCa. We conclude that the antitumor capacity of trabectedin is not only due to its effects on tumor cells, but also to the modulation of the tumor microenvironment, due, at least in part, to the modulation of the expression of different macrophage ion channels., This research was funded by AEI, Grants SAF2016-75021-R (to CV) funded by MICIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”; Grants PID2019-104366RB-C21 (to CV) and PID2020-113238RB-I00 (to L.B.) funded by MCIN/AEI/10.13039/501100011033; by CIBERCV, Grant CB/11/00222 funded by Instituto de Salud Carlos III (to LB and CV) co-financed by the European Development Regional Fund “A Way to Achieve Europe”); Comunidad de Madrid Programa Biociencias (P2022-BMD-7223); by CSIC Grants PIE201820E104 and 2019AEP148 (to CV). This research was partially funded by a grant from a PharmaMar S.A. Grant., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Resolvin D2 Attenuates Cardiovascular Damage in Angiotensin II-Induced Hypertension

  • Díaz del Campo, Lucía S.
  • García-Redondo, Ana B.
  • Rodríguez, Cristina
  • Zaragoza, Carlos
  • Duro-Sánchez, Santiago
  • Palmas, Francesco
  • Benito-Bueno, Ángela de
  • Socuéllamos, Paula G.
  • Peraza, Diego A.
  • Rodrigues-Díez, Raquel
  • Valenzuela, Carmen
  • Dalli, Jesmond
  • Salaices, Mercedes
  • Briones, Ana M.
[Background]: Resolution of inflammation is orchestrated by specialized proresolving lipid mediators (SPMs), and this would be impaired in some cardiovascular diseases. Among SPMs, resolvins (Rv) have beneficial effects in cardiovascular pathologies, but little is known about their effect on cardiovascular damage in hypertension., [Methods:]: Aorta, small mesenteric arteries, heart, and peritoneal macrophages were taken from C57BL/6J mice, infused or not with angiotensin II (AngII; 1.44 mg/kg/day, 14 days) in presence or absence of resolvin D2 (RvD2) (100 ng/mice, every second day) starting 1 day before or 7 days after AngII infusion., [Results]: Enzymes and receptors involved in SPMs biosynthesis and signaling were increased in aorta or heart from AngII-infused mice. We also observed a differential regulation of SPMs in heart from these mice. Preventive treatment with RvD2 partially avoided AngII-induced hypertension and protected the heart and large and small vessels against functional and structural alterations induced by AngII. RvD2 increased the availability of vasoprotective factors, modified SPMs profile, decreased cardiovascular fibrosis, and increased the infiltration of pro-resolving macrophages. When administered in hypertensive animals with established cardiovascular damage, RvD2 partially improved cardiovascular function and structure, decreased fibrosis, reduced the infiltration of neutrophils, and shifted macrophage phenotype toward a pro-resolving phenotype., [Conclusions]: There is a disbalance between proinflammatory and resolution mediators in hypertension. RvD2 protects cardiovascular function and structure when administered before and after the development of hypertension by modulating vascular factors, fibrosis and inflammation. Activating resolution mechanisms by treatment with RvD2 may represent a novel therapeutic strategy for the treatment of hypertensive cardiovascular disease., This work is supported by SAF2016-80305P (to M. Salaices and A.M. Briones), SAF2016-75021-R (to C. Valenzuela) funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”; PID2020-116498RB-I00 (to A.M. Briones), PID2019-104366RB-C21 (to C. Valenzuela) funded by MCIN/AEI/10.13039/501100011033, Grant from Comunidad de Madrid (CM) (B2017/BMD-3676 AORTASANA) FEDER— way to build Europe (to M. Salaices); Grant of the Instituto de Salud Carlos III PI21/01048 (to C. Rodríguez); Grant of Consejo Superior de Investigaciones Cientificas: 2019AEP148 (to C. Valenzuela). The study has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement no. 954798 (to A.M. Briones). R. Rodrigues-Diez was supported by a Juan de la Cierva contract (IJCI-2017-31399). A. de Benito-Bueno is funded by the FPI (BES-2017-080184); P.G. Socuellamos is funded by the FPU (FPU17/02731). J. Dalli is supported by funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant no: 677542) and the Barts Charity (grant no: MGU0343)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Sigma-1 receptor modulation fine-tunes KV1.5 channels and impacts pulmonary vascular function

  • Vera-Zambrano, Alba
  • Baena-Nuevo, M.
  • Rinné, Susanne
  • Villegas-Esguevillas, Marta
  • Barreira, Bianca
  • Telli, Gokcen
  • Benito-Bueno, Ángela de
  • Blázquez, J. A.
  • Climent, Belén
  • Pérez-Vizcaíno, Francisco
  • Valenzuela, Carmen
  • Decher, Niels
  • González, Teresa
  • Cogolludo, Angel
KV1.5 channels are key players in the regulation of vascular tone and atrial excitability and their impairment is associated with cardiovascular diseases including pulmonary arterial hypertension (PAH) and atrial fibrillation (AF). Unfortunately, pharmacological strategies to improve KV1.5 channel function are missing. Herein, we aimed to study whether the chaperone sigma-1 receptor (S1R) is able to regulate these channels and represent a new strategy to enhance their function. By using different electrophysiological and molecular techniques in X. laevis oocytes and HEK293 cells, we demonstrate that S1R physically interacts with KV1.5 channels and regulate their expression and function. S1R induced a bimodal regulation of KV1.5 channel expression/activity, increasing it at low concentrations and decreasing it at high concentrations. Of note, S1R agonists (PRE084 and SKF10047) increased, whereas the S1R antagonist BD1047 decreased, KV1.5 expression and activity. Moreover, PRE084 markedly increased KV1.5 currents in pulmonary artery smooth muscle cells and attenuated vasoconstriction and proliferation in pulmonary arteries. We also show that both KV1.5 channels and S1R, at mRNA and protein levels, are clearly downregulated in samples from PAH and AF patients. Moreover, the expression of both genes showed a positive correlation. Finally, the ability of PRE084 to increase KV1.5 function was preserved under sustained hypoxic conditions, as an in vitro PAH model. Our study provides insight into the key role of S1R in modulating the expression and activity of KV1.5 channels and highlights the potential role of this chaperone as a novel pharmacological target for pathological conditions associated with KV1.5 channel dysfunction., This work was supported by Ministerio de Ciencia e Inovación [SAF2016-75021-R; PID2019-104366RB-C21 to C.V. and T.G., PID2020-117939RB-I00 to A.C., PID2019-107363RB-I00 to F.P.V.]; by CIBERCV, by Instituto de Salud Carlos III [CB/11/00222 to C.V.], by CSIC [PIE201820E104; 2019AEP148 to C.V.]. BES-2017-080184 (to A.B.-B.), funded by MCIN/AEI/ 10.13039/501100011033 and by “ESF Investing in your future” funded by Ministerio de Ciencia e Innovación. A.V.-Z., M.B.-N., A.B.-B. and M.V-E. was awarded with predoctoral fellowships: FPI-UAM, CSIC, FPI and FPU predoctoral contracts, respectively. A.V.-Z. was awarded with a Short-term fellowship from the European Molecular Biology Organization (EMBO)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

RvD1 and LXA4 inhibitory effects on cardiac voltage-gated potassium channels

  • Cruz, Alicia de la
  • Ronchi, Carlotta
  • Bartolucci, Chiara
  • Socuéllamos, Paula G.
  • Benito-Bueno, Ángela de
  • Severi, Stefano
  • Zaza, Antonio
  • Valenzuela, Carmen
The resolution of inflammation is modulated by specialized pro-resolving lipid mediators (SPMs), which can be modified in some cardiovascular diseases. Among these SPMs, RvD1 and LXA4 prevent atrial fibrillation (AF) remodeling and cardiac hypertrophy, respectively in animal models. However, little is known about their electrophysiological effects on cardiac voltage-gated (VG) ion channels. We used the patch-clamp technique in heterologous systems and cardiomyocytes to assess the acute effects of RvD1, and LXA4, on VG potassium currents. In silico simulations were used to predict the effect of current modulation on the atrial and ventricular action potentials (AP). RvD1 (5 nM) reduced IKs (channel KV7.1/KCNE1) in COS-7 cells and guinea-pig cardiomyocytes by 50.3 ± 7.3 % and 29.9 ± 5.4 % at + 40 mV, respectively, without modifying its voltage dependence. RvD1 was more potent than LXA4. In heterologous systems, RvD1 was also tested on IKur (channel KV1.5), Ito (channel KV4.3/KChIP2), IKr (channel KV11.1), and IK1 (channel Kir2.1) with the largest inhibitory effect on IKs and IKr. In in silico simulations RvD1 prolonged repolarization significantly in both atrial and ventricular myocytes. All these results provide a comprehensive evaluation of RvD1 and LXA4 on cardiac human potassium channels, at pathophysiologically relevant concentrations, being RvD1 more potent than LXA4. The predicted effects on the AP suggest that, along with their antiinflammatory action, RvD1 may reverse AF-induced electrical remodeling in the atria by their modulation of K+ currents. The same action might instead contribute to ventricular functional remodeling; however, direct evidence for this is missing., This publication is the results of the: Grants PID2019–104366RB-C21 (to C.V.), PID2022–137214OB-C21 (to C.V.); funded by MCIN/AEI/10.13039/501100011033; Grant CB/11/00222 funded by Instituto de Salud Carlos III CIBERCV (to C.V.); Grants BES-2017–080184 (to A.d.B.-B.); Grant FPU17/02731 (to P.G.S.) funded by Ministerio de Ciencia e Innovación. NextGenerationEU through the Italian Ministry of University (C.B. and S.S) and Research under PNRR - M4C2-I1.3 Project PR 00000019 “HEAL ITALIA” (to S.S). CUP J33C22002920006 (C.B. and S.S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Lgi3-4 proteins modulate the KV1.5 channelosome and are potential therapeutic targets for atrial fibrillation

  • Socuéllamos, Paula G.
  • Macías, Álvaro
  • Benito-Bueno, Ángela de
  • Cruz, Francisco M.
  • Redondo-Moya, María
  • Coronado, María José
  • Ramil, Elvira
  • Rosado, Silvia
  • Rios-Rosado, Elsa Carolina
  • Valencia-Avezuela, María
  • Andrés-Delgado, Laura
  • Blázquez, José Antonio
  • Forteza-Gil, Alberto
  • Gutiérrez-Rodríguez, Marta
  • Jalife, José
  • Valenzuela, Carmen
We investigated the role of Lgi3-4 proteins in cardiac electrophysiology, with a specific focus on IKur, and their potential contribution to the pathophysiology of atrial fibrillation (AF)., Supported by Grants PID2019-104366RB-C21 (to C.V.), PID2019-104366RB-C22 (to M.G-R.), PID2022-137214OB-C21 (to C.V.); PID2022-137214OB-C22 (to M.G-R.) funded by MCIN/ AEI/10.13039/501100011033; Grant CB/11/00222 funded by Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (to C.V.); Grant S2022/BMD-7223 by Comunidad Autónoma de Madrid (CAM) (to C.V.); Grant FPU17/ 02731 (to P.G.S.); Grant BES-2017-080184 (to A.d.B.-B.); funded by Ministerio de Ciencia e Innovación. Supported also by National Heart, Lung and Blood Institute, NIH, grant number R01HL163943; La Caixa Banking Foundation project code HR18-00304 (LCF/PR/HR19/52160013); grants PI-FIS-2020 # PI20/01220 and PI-FIS-2023 # PI23/01039 from Instituto de Salud Carlos III (ISCIII) and co-funded by Fondo Europeo de Desarrollo Regional (FEDER), and by The European Union, respectively; grant PID2020-116935RB-I00 and BFU2016-75144-R funded by MCIN/AEI/10.13039/501100011033; Fundación La Marató de TV3 (736/C/2020) ‘amb el suport de la Fundació La Marató de TV3’; CIBERCV (CB16/11/00458; CB/11/00222 to CV); European Union’s Horizon 2020 grant agreement GA-965286; and Program S2022/BMD7229-CM ARCADIA-CM funded by Comunidad de Madrid (to JJ)., Peer reviewed